GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

GRNQ · Sep 30, 2023

Greenpro Capital Corp.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001493152-23-040246General Corporate
Capex intensity25thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

-0.00% · OPTIONAL · VALID

Operating cash generation94thOwn-history percentile · N=18
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-18.57% · OPTIONAL · VALID

Revenue growth43thOwn-history percentile · N=14
Evidence method

Yoy · gp.fundamentals.revenue

-18.02% · CORE · VALID

Gross margin50thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.gross_margin

78.57% · CORE · VALID

Operating margin94thOwn-history percentile · N=18
Evidence method

Level · gp.fundamentals.operating_margin

-12.75% · CORE · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History30 statesSelf-history eligible
Period transition

What moved in the state?

Cash Generation Increased
Previous
-57.11%
Current
-18.57%
Delta
38.54%
Growth Increased
Previous
-25.63%
Current
-18.02%
Delta
7.60%
Margin Decreased
Previous
84.24%
Current
78.57%
Delta
-5.67%
Profitability Increased
Previous
-51.77%
Current
-12.75%
Delta
39.02%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.